Stockscreener 앱 받기
125.01
0.47%
-0.59
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Neurological Disorder Drugs Market Set to Witness Significant - openPR.com
Will Neurocrine Biosciences Inc. bounce back from current supportWatchlist Summary for Active Day Traders - Newser
Top chart patterns to watch in Neurocrine Biosciences Inc.5-Year Price Trend Summary and Analysis - Newser
What’s next for Neurocrine Biosciences Inc. stock priceFree Daily Growth Stock Pick Reports - Newser
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025 - GlobeNewswire Inc.
Neurocrine Biosciences shares rise 3.11% after-hours following Nxera Pharma's obesity pipeline progress. - AInvest
This Neurocrine Biosciences Insider Reduced Their Stake By 28% - 富途牛牛
Neurocrine CEO and IR Chief to Share Latest Growth Strategy at Major Biotech Conference - Stock Titan
Neurocrine Biosciences shares fall 1.10% intraday as Nxera Pharma launches obesity drug pipeline. - AInvest
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Tardive Dyskinesia Drugs Market Exclusive Report with Detailed - openPR.com
Guggenheim Boosts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $175.00 - MarketBeat
Trendlines Converge — Decision Point for Neurocrine Biosciences Inc.Secure Capital Picks With Upside Potential Tracked - metal.it
CRENESSITY's Breakout Launch Might Change the Case for Investing in Neurocrine Biosciences (NBIX) - simplywall.st
What drives Neurocrine Biosciences Inc. stock priceUnlock powerful trading alerts for success - Jammu Links News
Is Neurocrine Biosciences Inc. a growth stock or a value stockTremendous wealth creation - Jammu Links News
Neurocrine Biosciences Inc. Stock Analysis and ForecastRapid portfolio appreciation - Jammu Links News
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $144.00 at Royal Bank Of Canada - MarketBeat
How does Neurocrine Biosciences Inc. generate profit in a changing economyMaximize portfolio value with smart investment plans - Jammu Links News
How many analysts rate Neurocrine Biosciences Inc. as a “Buy”Dynamic growth stocks - Jammu Links News
What is the risk reward ratio of investing in Neurocrine Biosciences Inc. stockAchieve consistent profits with expert advice - Jammu Links News
What makes Neurocrine Biosciences Inc. stock price move sharplyStay ahead with daily market updates - Jammu Links News
What is the dividend policy of Neurocrine Biosciences Inc. stockAchieve rapid financial growth with expert picks - Jammu Links News
Contradictions in Focus: Analyzing INGREZZA and Crinecerfont's Market Dynamics and Pricing Strategies - AInvest
How volatile is Neurocrine Biosciences Inc. stock compared to the marketExplosive earnings growth - Jammu Links News
Is Neurocrine Biosciences Inc. stock overvalued or undervaluedGet daily updates on promising stocks - Jammu Links News
What institutional investors are buying Neurocrine Biosciences Inc. stockUnlock real-time stock alerts for quick profits - Jammu Links News
Neurocrine Biosciences chief commercial officer sells $115,940 in stock - MSN
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2025 Earnings Call Transcript - Insider Monkey
Research Alert: CFRA Retains Hold Opinion On Shares Of Neurocrine Biosciences, Inc. - 富途牛牛
Neurocrine's Promising Outlook: Strong Crenessity Sales and Strategic Ingrezza Adjustments Drive Buy Rating. - AInvest
Guggenheim Raises Price Target for Neurocrine Biosciences, Maintains "Buy" Rating - AInvest
Neurocrine Biosciences’ Promising MDD Treatment Study: Key Insights for Investors - TipRanks
Neurocrine Biosciences: Guggenheim raises PT to $175, maintains Buy rating. - AInvest
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $140 to $200 - 富途牛牛
Neurocrine Biosciences Second Quarter 2025 Earnings: Beats Expectations - simplywall.st
Neurocrine (NBIX) Q2 Revenue Jumps 17% - Nasdaq
Neurocrine Biosciences’ Earnings Call Highlights Growth - TipRanks
Neurocrine Biosciences: JP Morgan Maintains Neutral, PT Raised to $145. - AInvest
The Analyst Verdict: Neurocrine Biosciences In The Eyes Of 17 Experts - 富途牛牛
Guggenheim raises Neurocrine Bio. stock price target on strong Ingrezza sales - Investing.com Canada
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $141 to $192 - 富途牛牛
Prime Medicine is selling $125M in stock; Nuvectis stops work on ovarian cancer drug - Endpoints News
Neurocrine Bio. price target raised to $145 from $140 at Mizuho - Investing.com Canada
Neurocrine Biosciences: Wedbush raises PT to $141, maintains Outperform rating. - AInvest
Neurocrine Biosciences Positioned For Growth And New Potential Blockbusters (NASDAQ:NBIX) - Seeking Alpha
Should you hold or exit Neurocrine Biosciences Inc. nowExpert Verified Stock Trade Ideas Backed by Data - metal.it
Neurocrine Bio. stock price target raised by BMO Capital to $124 - Investing.com
Neurocrine refines INGREZZA net sales guidance to $2.5B-$2.55B while CRENESSITY surges, driving revenue growth and pipeline expansion - MSN
Neurocrine: Q2 Earnings Snapshot - Connecticut Post
Strong Earnings and Pipeline Progress Could Be a Game Changer for Neurocrine Biosciences (NBIX) - simplywall.st
Neurocrine Biosciences 2025 Q2 Earnings Strong Growth as Net Income Rises 65.4% - AInvest
Neurocrine Biosciences (NBIX): Navigating Pricing Pressures While Delivering Strong Sales Growth in Q2 2025 - AInvest
Neurocrine Biosciences Inc (NBIX) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
Schizophrenia Market Size 2034: Clinical Trials, EMA, PDMA, FDA - openPR.com
Neurocrine Biosciences' Strategic Momentum in Movement Disorder Therapies: A Deep Dive into INGREZZA's Sustained Growth and CRENESSITY's Emerging Potential - AInvest
Neurocrine Biosciences Q2 2025 Earnings Call: INGREZZA Sets New Sales Records, CRENESSITY Surges, and Revenue Growth Soars. - AInvest
Neurocrine Biosciences, Inc. 2025 Q2 Earnings and Strategic Momentum: A Deep Dive into Long-Term Growth Potential - AInvest
Earnings call transcript: Neurocrine Biosciences Q2 2025 earnings beat expectations - Investing.com Australia
Earnings call transcript: Neurocrine Biosciences Q2 2025 earnings beat expectations By Investing.com - Investing.com South Africa
Neurocrine Biosciences' Q2 2025 Outperformance: A Case for Sustainable Growth and Premium Valuation - AInvest
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings - Yahoo Finance
1.47%
자본화:
|
볼륨(24시간):